IL122892A0 - Pharmaceutical compositions comprising a thiocarbamate - Google Patents

Pharmaceutical compositions comprising a thiocarbamate

Info

Publication number
IL122892A0
IL122892A0 IL12289298A IL12289298A IL122892A0 IL 122892 A0 IL122892 A0 IL 122892A0 IL 12289298 A IL12289298 A IL 12289298A IL 12289298 A IL12289298 A IL 12289298A IL 122892 A0 IL122892 A0 IL 122892A0
Authority
IL
Israel
Prior art keywords
thiocarbamate
pharmaceutical compositions
angiogenesis
disulfiram
useful
Prior art date
Application number
IL12289298A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL12289298A priority Critical patent/IL122892A0/xx
Publication of IL122892A0 publication Critical patent/IL122892A0/xx
Priority to JP2000527235A priority patent/JP2002500180A/ja
Priority to DK99900280T priority patent/DK1047416T3/da
Priority to AU18885/99A priority patent/AU1888599A/en
Priority to AT99900280T priority patent/ATE401879T1/de
Priority to US09/582,995 priority patent/US6288110B1/en
Priority to EP99900280A priority patent/EP1047416B1/en
Priority to DE69939155T priority patent/DE69939155D1/de
Priority to PCT/IL1999/000017 priority patent/WO1999034784A2/en
Priority to IL13720999A priority patent/IL137209A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
IL12289298A 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate IL122892A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
JP2000527235A JP2002500180A (ja) 1998-01-11 1999-01-11 ジスルフィラムで構成される医薬品組成物
DK99900280T DK1047416T3 (da) 1998-01-11 1999-01-11 Farmaceutiske præparater der omfatter disulfiram til inhibering af angionese
AU18885/99A AU1888599A (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram
AT99900280T ATE401879T1 (de) 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel
US09/582,995 US6288110B1 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram
EP99900280A EP1047416B1 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
DE69939155T DE69939155D1 (de) 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis
IL13720999A IL137209A0 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate

Publications (1)

Publication Number Publication Date
IL122892A0 true IL122892A0 (en) 1998-08-16

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6589987B2 (en) * 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
ATE552837T1 (de) * 2005-12-02 2012-04-15 Univ Johns Hopkins Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2012028311A1 (en) * 2010-08-31 2012-03-08 Avidal Vascular Gmbh Compositions comprising a taxane for coating medical devices
JP6206939B2 (ja) * 2011-10-11 2017-10-04 国立大学法人 千葉大学 肝がん幹細胞阻害剤
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20160346231A1 (en) * 2014-02-06 2016-12-01 Texas Tech University System Disulfiram Compositions and Treatments for Brain Tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
EP3449919B1 (en) 2016-04-13 2024-05-01 University of Wolverhampton Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
EP3597221B1 (en) 2017-03-17 2023-08-30 Osaka University Agents for the treatment of retinal degeneration and conditions associated with light reception
BR112020025018A2 (pt) * 2018-06-27 2021-03-23 Children's Medical Center Corporation compostos para inibição de inflamação
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
CA3173515A1 (en) * 2020-04-16 2021-10-21 Steven C. Quay Compositions and methods to reduce the infectivity of a virus
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
EP1047416B1 (en) 2008-07-23
WO1999034784A3 (en) 2000-09-08
DK1047416T3 (da) 2008-11-17
DE69939155D1 (de) 2008-09-04
AU1888599A (en) 1999-07-26
US6288110B1 (en) 2001-09-11
WO1999034784A2 (en) 1999-07-15
JP2002500180A (ja) 2002-01-08
ATE401879T1 (de) 2008-08-15
EP1047416A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL122892A0 (en) Pharmaceutical compositions comprising a thiocarbamate
FI935306A7 (fi) Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana
HU9701059D0 (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
MY128337A (en) New combination of steroids
MY111709A (en) Surgical cable.
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
IT8803711A0 (it) Apparecchiatura per prevenire la formazione e curare le piaghe da decubito in pazienti lungodegenti
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
BR0014996A (pt) Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
PL339836A1 (en) Phtalazine compounds and therapeutic agents suitable to treat erection disorders
NZ326345A (en) Composition containing diosgenin
SI1173179T1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent major depressive disorders
ATE230995T1 (de) Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
WO1999034763A3 (en) Pharmaceutical compositions comprising thiram for inhibiting angiogenesis
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
FI954675L (fi) Luonnollinen ja terveellinen mehu, yhdistelmä välttämättömistä ravintoaineista kehon toimintaa varten
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
IT1244562B (it) Agente per la prevenzione ed il trattamento dell'opacita' del cristallino.
ES2193741T3 (es) Aplicacion del gluconato de litio en terapia.
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal
IT1282904B1 (it) Macchinario per l'esercizio dei muscoli facciali e per il miglioramento dell'aspetto estetico del viso